Skip to main content
Clinical Trials/NCT01778010
NCT01778010
Completed
Phase 2

Modafinil in a Human Laboratory Model of Cocaine Relapse

New York State Psychiatric Institute1 site in 1 country8 target enrollmentMarch 2009

Overview

Phase
Phase 2
Intervention
Cocaine 0 mg
Conditions
Cocaine Dependence
Sponsor
New York State Psychiatric Institute
Enrollment
8
Locations
1
Primary Endpoint
Cocaine Self-administration
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Modafinil has been reported to reduce cocaine use in a clinical sample of infrequent users (2 days/week), but the effects of modafinil on cocaine self-administration in the laboratory have not been studied. The present study investigated the effects of modafinil maintenance on cocaine self-administration by frequent users (4 days/week) under controlled laboratory conditions. During this 48-day double-blind, crossover design study, the effects of modafinil maintenance (0, 200, and 400mg/day) on response to smoked cocaine (0, 12, 25, and 50 mg) were examined in nontreatment seeking cocaine-dependent individuals (n = 8).

Registry
clinicaltrials.gov
Start Date
March 2009
End Date
June 2013
Last Updated
8 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Smokes cocaine
  • Has patterns of smoked cocaine use in terms of frequency and amount which parallel or exceed those administered in the study.
  • Able to give informed consent, and comply with study procedures.
  • Normal body weight Within normal weight range (for appropriate frame) according to 1983 Metropolitan Weight tables -

Exclusion Criteria

  • Current seizure disorder, heart disease or a history of serious adverse effects due to cocaine.
  • Dependence on substances (other than cocaine or nicotine) or a history of dependence on alcohol
  • Request for drug treatment
  • Judged to be noncompliant with study protocol.
  • Current use of any psychotropic medication.
  • Clinical laboratory tests outside normal limits that are clinically unacceptable to the study physician (BP \> 140/90; BUN, creatinine, LFTs \> 3x ULN; hematocrit \< 34 for women, \< 36 for men; pseudocholinesterase deficiency)
  • History of myocardial infarction or ischemia, clinically significant left ventricular hypertrophy, angina, clinically significant arrhythmia, or mitral valve prolapse
  • Currently meeting DSM-IV criteria for all major psychiatric/psychotic disorders other than transient psychosis due to drug abuse
  • Current parole or probation Self-report during interview -

Arms & Interventions

Modafinil 200mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 0 mg

Modafinil 200mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 12 mg

Modafinil 0mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Modafinil 0 mg

Modafinil 0mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 0 mg

Modafinil 0mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 12 mg

Modafinil 0mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 25 mg

Modafinil 0mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 50 mg

Modafinil 200mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Modafinil 200 mg

Modafinil 200mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 25 mg

Modafinil 200mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 50 mg

Modafinil 400mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Modafinil 400 mg

Modafinil 400mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 0 mg

Modafinil 400mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 12 mg

Modafinil 400mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 25 mg

Modafinil 400mg + Cocaine 0, 12, 25, 50 mg

Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.

Intervention: Cocaine 50 mg

Outcomes

Primary Outcomes

Cocaine Self-administration

Time Frame: 48 days

The number of purchased cocaine doses as a function of cocaine dose and modafinil maintenance condition.

Secondary Outcomes

  • Heart Rate(48 days)
  • Drug Quality Cluster(48 days)

Study Sites (1)

Loading locations...

Similar Trials